In terms of these univariable results, MPVI or EHS or both, AFP < 200 ng/mL, disease site, hepatitis B aetiology, and receipt of a previous procedure are all predictive of overall survival and adjusting for them influences the estimated hazard ratio of the treatment effect in favour of lenvatinib. The gene discussed is AFP; the disease is hepatitis B virus infection.